Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3186899 Phase 1 Study in Healthy Participants
NCT03874234Phase 1Terminated
- Sponsor
- GSK
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3186899 in visceral leishmaniasis (VL) (5 arms), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events and Serious Adverse Events, Number of Participants With Worst Case Hematology Results by Potential Clinical Importance (PCI) Criteria and 5 more. Started Apr 2019; status: terminated.
02
Drugs
GSK3186899
03
Conditions
visceral leishmaniasis (VL)
Beyond the preview
Go deeper on NCT03874234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874234.